

2005

HIGHPOINTS

JANUARY

An additional strategic advantage for business development and for the commercial launch of the 125L Ozone Sterilizer in the United States:

Michael Ward, a professional with an extensive background in sales who has been very successful in the field of sterilization, joins our team as Sales Director – U.S. market.

APRIL

British government subsidizes testing on the capacity of the 125L Ozone Sterilizer from TSO₃ to inactivate prions:

The Health Protection Agency (HPA) in the United Kingdom is testing the 125L Ozone Sterilizer for the inactivation of the prion, an infectious protein responsible for Creutzfeldt-Jakob disease. The project will extend over a period of about three years.

MAY

Dr. Paul S. Malchesky, a renowned researcher, puts his expertise to work for the TSO₃ Scientific Committee:

Specialized notably in the development of innovative technologies, Dr. Malchesky was formerly Vice President, Research and Development, Scientific Services and Investigational Studies, at STERIS Corporation – the biggest sterilization company in North America.

Added value for the promotion of the 125L Ozone Sterilizer thanks to the compatibility endorsements from two leading American manufacturers:

The Richard Wolf Company, the leader in the development and production of high quality optics, and Volk Optical, a recognized leader in aspheric optics, support and suggest the ozone sterilization of their products.

JULY

Securing of TSO₃ financial position with the closing of a \$10 million private placement:

Made through a syndicate of underwriters, this financing is a sign of the interest and confidence in TSO₃ by the investment community and secures the financial position of the Company.

The field of utilization for the 125L Ozone Sterilizer broadens:

TSO₃ extends its product claim by increasing its capacity to sterilize a greater variety of instruments that include instruments for micro-invasive surgery.

OCTOBER

First sale of the 125L Ozone Sterilizer is full of promise:

Responding to a request for a quotation, TSO₃ completes the first firm sale with a North American hospital after the sterilizer was submitted to a rigorous evaluation process. During this evaluation, the 125L had to meet several performance criteria and compared favourably to the competition.

DECEMBER

The sales team is reinforced with four new experienced resources:

The opening of four new positions for regional sales managers supports the commercialization efforts for the 125L Ozone Sterilizer.

Positive reports on the 125L Ozone Sterilizer from two U.S. referral sites:

"Economical," "Simple," "Reliable" and "Safe for hospitals" are among the conclusions in the written reports from users and managers in hospital settings.